7.9 USD
+0.07 (+0.89%)
7.9 USD
0 (0%)
Taking everything into account, LFCR scores 2 out of 10 in our fundamental rating. LFCR was compared to 58 industry peers in the Life Sciences Tools & Services industry. LFCR may be in some trouble as it scores bad on both profitability and health. LFCR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
LFCR had negative earnings in the past year.
LFCR had a positive operating cash flow in the past year.
In the past 5 years LFCR reported 4 times negative net income.
LFCR had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
LFCR has a worse Return On Assets (-16.60%) than 62.07% of its industry peers.
LFCR has a worse Return On Equity (-106.13%) than 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.6% | ||
| ROE | -106.13% | ||
| ROIC | N/A |
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 31.57%, LFCR is not doing good in the industry: 67.24% of the companies in the same industry are doing better.
LFCR's Gross Margin has improved in the last couple of years.
LFCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
2. Health
2.1 Basic Checks
LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFCR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LFCR has been increased compared to 5 years ago.
LFCR has a worse debt/assets ratio than last year.
2.2 Solvency
LFCR has an Altman-Z score of 0.41. This is a bad value and indicates that LFCR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.41, LFCR is not doing good in the industry: 74.14% of the companies in the same industry are doing better.
LFCR has a Debt/Equity ratio of 3.67. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of LFCR (3.67) is worse than 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.67 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.41 |
ROIC/WACCN/A
WACC8.85%
2.3 Liquidity
LFCR has a Current Ratio of 2.80. This indicates that LFCR is financially healthy and has no problem in meeting its short term obligations.
LFCR has a Current ratio of 2.80. This is comparable to the rest of the industry: LFCR outperforms 53.45% of its industry peers.
LFCR has a Quick Ratio of 1.67. This is a normal value and indicates that LFCR is financially healthy and should not expect problems in meeting its short term obligations.
LFCR has a Quick ratio (1.67) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.8 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
The earnings per share for LFCR have decreased strongly by -2114.69% in the last year.
Looking at the last year, LFCR shows a small growth in Revenue. The Revenue has grown by 5.31% in the last year.
LFCR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.25% yearly.
EPS 1Y (TTM)-2114.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
Revenue 1Y (TTM)5.31%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%25.93%
3.2 Future
The Earnings Per Share is expected to grow by 23.41% on average over the next years. This is a very strong growth
LFCR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.24% yearly.
EPS Next Y41.64%
EPS Next 2Y28.63%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue Next Year3.52%
Revenue Next 2Y7.18%
Revenue Next 3Y11.96%
Revenue Next 5Y21.24%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
LFCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LFCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of LFCR is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 73.31 |
4.3 Compensation for Growth
LFCR's earnings are expected to grow with 23.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.63%
EPS Next 3Y23.41%
5. Dividend
5.1 Amount
LFCR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.9
+0.07 (+0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners76.4%
Inst Owner ChangeN/A
Ins Owners1.8%
Ins Owner Change6.55%
Market Cap296.01M
Revenue(TTM)135.27M
Net Income(TTM)-39.04M
Analysts80
Price Target8.93 (13.04%)
Short Float %7%
Short Ratio13.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.27%
Min EPS beat(2)-1.54%
Max EPS beat(2)38.08%
EPS beat(4)2
Avg EPS beat(4)-38.79%
Min EPS beat(4)-207.19%
Max EPS beat(4)38.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.91%
Min Revenue beat(2)1.03%
Max Revenue beat(2)8.78%
Revenue beat(4)4
Avg Revenue beat(4)5.21%
Min Revenue beat(4)1.03%
Max Revenue beat(4)8.78%
Revenue beat(8)6
Avg Revenue beat(8)3.57%
Revenue beat(12)7
Avg Revenue beat(12)-4.62%
Revenue beat(16)8
Avg Revenue beat(16)-9.52%
PT rev (1m)-12.5%
PT rev (3m)-12.5%
EPS NQ rev (1m)-6.5%
EPS NQ rev (3m)-7.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.23%
Revenue NQ rev (1m)-3.7%
Revenue NQ rev (3m)-2.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.19 | ||
| P/FCF | N/A | ||
| P/OCF | 134.61 | ||
| P/B | 8.05 | ||
| P/tB | 15.83 | ||
| EV/EBITDA | 73.31 |
EPS(TTM)-1.07
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)0.06
OCFY0.74%
SpS3.61
BVpS0.98
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.6% | ||
| ROE | -106.13% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.57% | ||
| FCFM | N/A |
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
F-Score4
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.67 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 24.11 | ||
| Cap/Depr | 146.73% | ||
| Cap/Sales | 8.69% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 39.27% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.8 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 0.41 |
F-Score4
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)177.04%
Cap/Depr(5y)161.61%
Cap/Sales(3y)15.06%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2114.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
EPS Next Y41.64%
EPS Next 2Y28.63%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue 1Y (TTM)5.31%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%25.93%
Revenue Next Year3.52%
Revenue Next 2Y7.18%
Revenue Next 3Y11.96%
Revenue Next 5Y21.24%
EBIT growth 1Y60.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year656.28%
EBIT Next 3Y128.86%
EBIT Next 5YN/A
FCF growth 1Y80.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y109.07%
OCF growth 3YN/A
OCF growth 5YN/A
LIFECORE BIOMEDICAL INC / LFCR FAQ
What is the fundamental rating for LFCR stock?
ChartMill assigns a fundamental rating of 2 / 10 to LFCR.
What is the valuation status of LIFECORE BIOMEDICAL INC (LFCR) stock?
ChartMill assigns a valuation rating of 1 / 10 to LIFECORE BIOMEDICAL INC (LFCR). This can be considered as Overvalued.
Can you provide the profitability details for LIFECORE BIOMEDICAL INC?
LIFECORE BIOMEDICAL INC (LFCR) has a profitability rating of 1 / 10.
What is the expected EPS growth for LIFECORE BIOMEDICAL INC (LFCR) stock?
The Earnings per Share (EPS) of LIFECORE BIOMEDICAL INC (LFCR) is expected to grow by 41.64% in the next year.